<DOC>
	<DOCNO>NCT00467116</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some find tumor cell help kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Cetuximab may also stop growth tumor cell block blood flow tumor . Radiation therapy use high-energy x-ray kill tumor cell . Gemcitabine cetuximab may make tumor cell sensitive radiation therapy . Giving gemcitabine together cetuximab radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose gemcitabine give together cetuximab radiation therapy treat patient locally advanced pancreatic cancer remove surgery .</brief_summary>
	<brief_title>PhI Study Erbitux &amp; Gemcitabine w/Radiation Therapy Locally Adv . Pancreas Ca</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose gemcitabine hydrochloride administer cetuximab radiotherapy patient unresectable locally advanced pancreatic periampullary region cancer . - Determine toxicity regimen patient . OUTLINE : This dose-escalation study gemcitabine hydrochloride . Patients receive cetuximab IV 1-2 hour weekly week 1-7 gemcitabine hydrochloride IV 15-40 minute weekly week 2-7 . Patients also undergo radiotherapy 5 day week week 2-7 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow 30 day every 3 month thereafter . PROJECTED ACCRUAL : A total 12-30 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Histologically confirm adenocarcinoma pancreas ( head , body , tail ) periampullary region , meet follow criterion : Unresectable disease Locally advance disease Measurable evaluable disease CT scan MRI No evidence metastatic disease outside plan irradiation field ECOG performance status 02 WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.5 g/dL AST ALT ≤ 5 time upper limit normal Bilirubin ≤ 2.0 mg/dL Creatinine ≤ 2.0 mg/dL No clinical indication compromise function nonirradiated kidney No secondary malignancy within past 5 year except resect nonmelanoma skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No acute hepatitis No known HIV infection No active uncontrolled infection No significant history uncontrolled cardiac disease , include follow : Hypertension Unstable angina Myocardial infarction within past 6 month Congestive heart failure Cardiomyopathy decrease ejection fraction No prior severe infusion reaction monoclonal antibody PRIOR CONCURRENT THERAPY : No prior radiotherapy plan field treatment No prior therapy specifically directly target EGFR pathway At least 14 day since prior surgery biopsy At least 28 day since prior bypass procedure More 5 year since prior concurrent chemotherapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>